ARCA Biopharma: COVID Treatment Phase 2B Data Coming In 2nd Quarter

ARCA Biopharma (ABIO) has a novel treatment for COVID-19 in the works. The phase 2b data will be released in the 2nd quarter. In a world of wild moves in biotechnology stocks, this little biotech is trading near its lows. When this possible treatment was announced back in early 2020, ARCA Biopharma jumped to a high of $22.00. It has now settled down around $4.75/share. With new variants of COVID-19 popping up, this virus will be with the world for decades to come. Treatments are going to be extremely important. While extremely speculative, this biotech may be worth a shot for an explosive move, if the data is positive.

(Click on image to enlarge)

Disclaimer: All comments made by InTheMoneyStocks, LLC and its subsidiaries, instructors, and representatives are for educational and informational purposes only and should not be construed as ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.